Beijing: A novel coronavirus vaccine has for the first time "largely protected" monkeys from infection during an animal trial, data from a Chinese pharmaceutical giant showed.

It is among a slew of vaccines being developed around the world as countries race to stop an outbreak that has infected around 2.7 million people globally and killed more than 190,000.

Nasdaq-listed Sinovac Biotech said it injected two different doses of its vaccine into eight rhesus macaque monkeys and exposed them to the virus three weeks later, and they did not develop infections.

All the monkeys "were largely protected against SARS-CoV-2 infection", Sinovac said in its findings.

Four macaques who received a high dose of the vaccine had "no detectable" amounts of the virus in their lungs seven days after they were administered the pathogen.

Another four monkeys given low doses showed an increase in the viral load in their bodies but appeared to have controlled the virus on their own, it said.

In contrast, four monkeys who were not given the vaccine fell ill from the virus and suffered severe pneumonia.

Sinovac published its results on the online server bioRxiv on April 19, three days after it began human trials, but its findings have yet to be peer reviewed by the global scientific community.

The vaccine, like most others, uses a chemically inactivated novel coronavirus pathogen to help the body build immunity against the real disease.

Tests had shown "good efficacy" and the Beijing-based company was confident about the vaccine's potential, Sinovac spokeswoman Yang Guang told AFP.

The company had given "the first serious pre-clinical data I have seen for an actual vaccine candidate", said Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai in New York.

Krammer recently co-authored a survey of different coronavirus vaccine projects for the journal Cell.

He said on Twitter that the vaccine's use of inactivated viruses was "old-fashioned technology" which would make it easier to scale up production.

Several strains of the novel coronavirus have been found by researchers, showing that the pathogen slowly mutates, potentially making the development of a vaccine harder.

But Sinovac said its experiment so far had shown its vaccine can "neutralise" widely different strains found among patients in China, Italy, Switzerland, Spain and Britain.

"This provides strong evidence that the virus is not mutating in a way that would make it resistant to a #COVID19 vaccine," immunologist Mark Slifka from Oregon Health & Science University tweeted.

However, vaccines with inactive pathogens need booster shots to stay effective and it remained to be seen whether Sinovac's research would provide "long-lasting protection" from the virus, said Lucy Walker, professor of immune regulation at University College London.

Phase three testing of the vaccine will need human volunteers who were never infected with the disease as well as those with symptoms.

Sinovac's Yang said the company was looking abroad for test subjects as China now does not have enough reported COVID-19 cases.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.pulsus.com/submissions/biomolecules-biochemistry.html) or Author may submit their manuscripts as an e-mail attachment to the Editorial Office at: biomolecules@molecularbiologyjournals.com

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.

Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Mercy| Managing Editor
Journal of Biomolecules and Biochemistry
Whatsapp No:  +1-504-608-2390